Clinical Trials Arena is using cookies

We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.

ContinueLearn More X
X

Zynteglo for the Treatment of Transfusion-Dependent Beta-thalassemia

Drug Name

Zynteglo™

Developer

Bluebird Bio

Therapy Class

Gene therapy

Product Description

Autologous CD34+ cells encoding βA-T87Q-globin gene

Current Indication

Transfusion-dependent Beta-thalassemia

Market Sector

Genetics

Development Status

Approved in Europe
Expand
Close
Close
Close

Go Top